CN108635363A - It is a kind of to be used to substitute composition and its assay method that paris polyphylla prepares treatment of human cervical cancer drug - Google Patents
It is a kind of to be used to substitute composition and its assay method that paris polyphylla prepares treatment of human cervical cancer drug Download PDFInfo
- Publication number
- CN108635363A CN108635363A CN201810456610.0A CN201810456610A CN108635363A CN 108635363 A CN108635363 A CN 108635363A CN 201810456610 A CN201810456610 A CN 201810456610A CN 108635363 A CN108635363 A CN 108635363A
- Authority
- CN
- China
- Prior art keywords
- composition
- paris polyphylla
- rha
- chonglou saponin
- equivalent substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 241000244987 Daiswa polyphylla Species 0.000 title claims abstract description 76
- 206010008342 Cervix carcinoma Diseases 0.000 title claims abstract description 16
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title claims abstract description 16
- 201000010881 cervical cancer Diseases 0.000 title claims abstract description 16
- 239000003560 cancer drug Substances 0.000 title claims abstract description 14
- 238000003556 assay Methods 0.000 title abstract description 6
- 230000014509 gene expression Effects 0.000 claims abstract description 46
- SYYHBUHOUUETMI-UHFFFAOYSA-N Pennogenin Natural products O1C2CC3C4CC=C5CC(O)CCC5(C)C4CCC3(C)C2(O)C(C)C21CCC(C)CO2 SYYHBUHOUUETMI-UHFFFAOYSA-N 0.000 claims abstract description 27
- SYYHBUHOUUETMI-WJOMMTHPSA-N pennogenin Chemical compound C([C@@]12[C@H]([C@@]3([C@@]4(C)CC[C@@H]5[C@@]6(C)CC[C@H](O)CC6=CC[C@H]5[C@@H]4C[C@@H]3O2)O)C)C[C@@H](C)CO1 SYYHBUHOUUETMI-WJOMMTHPSA-N 0.000 claims abstract description 27
- 238000006467 substitution reaction Methods 0.000 claims abstract description 27
- FBFJAXUYHGSVFN-IYUYFXHASA-N 68124-04-9 Chemical compound C([C@@]12[C@H]([C@@]3([C@@]4(C)CC[C@@H]5[C@@]6(C)CC[C@@H](CC6=CC[C@H]5[C@@H]4C[C@@H]3O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@H](O)[C@@H](O[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)[C@H](C)O3)O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O)C)C[C@@H](C)CO1 FBFJAXUYHGSVFN-IYUYFXHASA-N 0.000 claims abstract description 25
- YQEMAEKYNNOCBY-UHFFFAOYSA-N (25R)-diosgenin-3-O-beta-D-glucopyranosyl(1-3)-[alpha-L-rhamnopyranosyl(1-2)]-beta-D-glucopyranoside Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C1OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O YQEMAEKYNNOCBY-UHFFFAOYSA-N 0.000 claims abstract description 24
- YQEMAEKYNNOCBY-IEMDQPGHSA-N Gracillin Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YQEMAEKYNNOCBY-IEMDQPGHSA-N 0.000 claims abstract description 24
- LDDIPQISQQULJN-DCXLXNQSSA-N gracillin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O LDDIPQISQQULJN-DCXLXNQSSA-N 0.000 claims abstract description 24
- LHHAGBJPCRSFHH-UHFFFAOYSA-N lilioglycoside G Natural products CC1CCC2(OC1)OC3CC4C5CC=C6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(O)C(OC8OC(CO)C(O)C(O)C8OC9OC(C)C(O)C(O)C9O)C7O LHHAGBJPCRSFHH-UHFFFAOYSA-N 0.000 claims abstract description 24
- KPOSIVPPNIGLFV-UHFFFAOYSA-N Saponin H Chemical compound CC(C)=CC(O)CC1(C)OC1C1C2(CC(=O)OC2)C2(C)CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC1 KPOSIVPPNIGLFV-UHFFFAOYSA-N 0.000 claims abstract description 22
- AWKXNOOUWFJCMU-UHFFFAOYSA-N n1953 Chemical compound O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1OC2C(C(O)C(O)C(C)O2)O)O)OC(CO)C1OC1OC(CO)C(O)C1O AWKXNOOUWFJCMU-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000003112 inhibitor Substances 0.000 claims abstract description 7
- 102100020814 Sequestosome-1 Human genes 0.000 claims abstract 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 54
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 54
- SHZGCJCMOBCMKK-HGVZOGFYSA-N alpha-L-rhamnopyranose Chemical compound C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-HGVZOGFYSA-N 0.000 claims description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 239000012071 phase Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 239000007791 liquid phase Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 11
- 239000003814 drug Substances 0.000 description 40
- IUCHKMAZAWJNBJ-RCYXVVTDSA-N oleanolic acid 3-O-beta-D-glucosiduronic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IUCHKMAZAWJNBJ-RCYXVVTDSA-N 0.000 description 20
- 102100024057 Nuclear pore glycoprotein p62 Human genes 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 15
- 101150097636 LSD1 gene Proteins 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 11
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- ZASFTWIDVOCZOL-KQSKSNQTSA-N (2s,3r,4s,5r,6r)-2-[(2s,3s,5r,6s)-6-[(2r,3r,4r,5s,6s)-5-hydroxy-4-methoxy-6-methyl-2-propoxyoxan-3-yl]oxy-4,5-dimethoxy-2-methyloxan-3-yl]oxy-4-methoxy-6-(methoxymethyl)oxane-3,5-diol Chemical compound CCCO[C@@H]1O[C@@H](C)[C@H](O)[C@@H](OC)[C@H]1O[C@H]1[C@H](OC)C(OC)[C@@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](O)[C@@H](COC)O2)O)[C@H](C)O1 ZASFTWIDVOCZOL-KQSKSNQTSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 230000002611 ovarian Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 102100037919 Insulin-like growth factor 2 mRNA-binding protein 2 Human genes 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 2
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000244962 Paris Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 1
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The composition and its assay method that the invention discloses a kind of to prepare treatment of human cervical cancer drug for substituting paris polyphylla.The composition being made of chonglou saponin VII, pennogenin 3 O α L Rha (1 → 2) [α L Rha (1 → 4)] β D Glc, chonglou saponin H, chonglou saponin II and Gracillin substantially can be with equivalent substitution paris polyphylla to p62 gene expressions depression effect, the two intensity is suitable；The composition can be used for equivalent substitution paris polyphylla and prepare p62 gene expression inhibitors；Those skilled in the art will know that, inhibit p62 gene expressions that can effectively inhibit proliferation (influence of the RNA AF panel p62 gene expressions to proliferation of cervical cancer HeLa cell of cervical cancer cell, Bengbu Medical College's journal the 1st phase of volume 43 in January, 2018), therefore, the composition can be used for equivalent substitution paris polyphylla and prepare treatment of human cervical cancer drug.
Description
Technical field
The present invention relates to a kind of compositions and its assay method preparing tumor therapeutic agent for substituting paris polyphylla.
Background technology
Paris Paris L. are broad sense liliaceous plant, and rhizome is used as medicine, and have clearing heat and detoxicating, swelling and pain relieving and cool liver
The effect of arresting convulsion, is mainly used for antitumor, hemostasis, immunological regulation, sedation and analgesia etc..The whole world has 24 kinds, and China has 19 kinds, master
It is distributed in the ground such as Yunnan, Sichuan, Guangxi, wherein paris polyphylla Paris polyphylla Smith var.Yunnanensis
(Franch.) Hand.-Mazz. quilts《Chinese Pharmacopoeia》Version is included within 2010.
At present since medical industry production is continuously increased Paris polyphylla demand so that wild Paris polyphylla is fewer and fewer, resource
It is increasingly exhausted.If can search out can substitute the composition that Paris polyphylla is used as medicine, so that it may be obtained greatly in the method blent with chemistry
Paris polyphylla substitute is measured, the present situation of Paris polyphylla resource anxiety is alleviated.
Mainly contained in paris polyphylla chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 →
4)]-β-D-Glc (PGRR), chonglou saponin H, chonglou saponin II, Gracillin, chonglou saponin I etc..At present, in this case it is not apparent that
Which kind combination can substitute the drug effect of Paris polyphylla substantially in these ingredients.
Invention content
An object of the present disclosure is to provide a kind of composition preparing tumor therapeutic agent for substituting paris polyphylla；
The present invention second is designed to provide the assay method of above-mentioned composition.
The purpose of the present invention is realized by following technical solution：
First part：Cervical carcinoma equivalent composition
A kind of composition preparing p62 gene expression inhibitors for equivalent substitution paris polyphylla：
By chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, Paris polyphylla
Saponin(e H, chonglou saponin II and Gracillin composition.
Application of the above-mentioned composition in terms of equivalent substitution paris polyphylla prepares p62 gene expression inhibitors.
A kind of composition preparing treatment of human cervical cancer drug for equivalent substitution paris polyphylla：
By chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, Paris polyphylla
Saponin(e H, chonglou saponin II and Gracillin composition.
Application of the above-mentioned composition in terms of equivalent substitution paris polyphylla prepares treatment of human cervical cancer drug.
A kind of HPLC methods of each chemical composition content in paris polyphylla in measurement above-mentioned composition, including following chromatography ginseng
Number：
Chromatographic column：C18 filler chromatographic columns；
Mobile phase：Acetonitrile (A)-water (B)；
Elution program：0~10min, 20%~30%A；10~20min, 30%~40%A；20~35min, 40%~
50%A；35~45min, 50%~60%A；45~55min, 60%~80%A；55~60min, 80%~100%A.
Preferably, using 1100 liquid chromatographs of Agilent.
Preferably, using Agilent ZORBAX Extend-C18 liquid-phase chromatographic columns.
It is highly preferred that chromatographic column specification is 250mm × 4.6mm, 5 μm.
Preferably, column temperature is 30 DEG C.
Preferably, Detection wavelength 210nm.
Preferably, flow rate of mobile phase 1.0mL/min.
Preferably, sample size is 20 μ L.
Second part：Oophoroma equivalent composition
A kind of composition preparing LSD1 gene expression inhibitors for equivalent substitution paris polyphylla：
By chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, Paris polyphylla
Saponin I I, Gracillin and chonglou saponin I compositions.
Application of the above-mentioned composition in terms of equivalent substitution paris polyphylla prepares LSD1 gene expression inhibitors.
A kind of composition preparing treatment of ovarian cancer drug for equivalent substitution paris polyphylla：
By chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, Paris polyphylla
Saponin I I, Gracillin and chonglou saponin I compositions.
Application of the above-mentioned composition in terms of equivalent substitution paris polyphylla prepares treatment of ovarian cancer drug.
A kind of HPLC methods of each chemical composition content in paris polyphylla in measurement above-mentioned composition, including following chromatography ginseng
Number：
Chromatographic column：C18 filler chromatographic columns；
Mobile phase：Acetonitrile (A)-water (B)；
Elution program：0~10min, 20%~30%A；10~20min, 30%~40%A；20~35min, 40%~
50%A；35~45min, 50%~60%A；45~55min, 60%~80%A；55~60min, 80%~100%A.
Preferably, using 1100 liquid chromatographs of Agilent.
Preferably, using Agilent ZORBAX Extend-C18 liquid-phase chromatographic columns.
It is highly preferred that chromatographic column specification is 250mm × 4.6mm, 5 μm.
Preferably, column temperature is 30 DEG C.
Preferably, Detection wavelength 210nm.
Preferably, flow rate of mobile phase 1.0mL/min.
Preferably, sample size is 20 μ L.
Advantageous effect：
(1) by chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, again
The composition of building saponin(e H, chonglou saponin II and Gracillin composition substantially can be with equivalent substitution paris polyphylla to p62 gene tables
The depression effect reached, the two intensity are suitable；The composition can be used for equivalent substitution paris polyphylla and prepare p62 gene expression inhibitions
Agent；One skilled in the art will appreciate that inhibition p62 gene expressions can effectively inhibit proliferation (the RNA AF panels of cervical cancer cell
Influence of the p62 gene expressions to proliferation of cervical cancer HeLa cell, Bengbu Medical College's journal the 1st phase of volume 43 in January, 2018), because
This, the composition can be used for equivalent substitution paris polyphylla and prepare treatment of human cervical cancer drug；
(2) by chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, again
In the composition of building saponin(e H, chonglou saponin II and Gracillin composition, pennogenin -3-O- α-L-Rha (1 → 2) [α -
L-Rha (1 → 4)]-β-D-Glc are 11% to the independent inhibiting rate of p62 gene expressions, other 4 kinds of ingredients are to p62 gene expressions
Combination inhibiting rate be 19%, group of significantly less than the 5 kinds ingredients of sum of the two (11%+19%=30%) to p62 gene expressions
The phenomenon that conjunction inhibiting rate 53%, this 2 1+1 ＜, embodies pennogenin -3-O- α-L-Rha (1 → 2) [α-L- in the composition
Rha (1 → 4)] there are the effects for significantly cooperate with inhibition p62 gene expressions in-β-D-Glc and other 4 kinds of ingredients；
(3) by chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, again
The composition of building saponin I I, Gracillin and chonglou saponin I compositions substantially can be with equivalent substitution paris polyphyllas to LSD1 genes
The depression effect of expression, the two intensity are suitable；The composition can be used for equivalent substitution paris polyphylla and prepare LSD1 gene expressions suppression
Preparation；One skilled in the art will appreciate that inhibition LSD1 gene expressions can effectively inhibit proliferation (the silence LSD1 of ovarian cancer cell
The expression of gene can inhibit the proliferation of oophoroma HO8910 cells and induce its apoptosis, tumour the 5th phase of volume 36 in May, 2016),
Therefore, the composition can be used for equivalent substitution paris polyphylla and prepare treatment of ovarian cancer drug；
(4) by chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, again
In the composition of building saponin I I, Gracillin and chonglou saponin I compositions, pennogenin -3-O- α-L-Rha (1 → 2) [α -
L-Rha (1 → 4)]-β-D-Glc are 12% to the independent inhibiting rate of LSD1 gene expressions, other 4 kinds of ingredients are to LSD1 gene tables
The combination inhibiting rate reached is 22%, and significantly less than 5 kinds ingredients of sum of the two (12%+22%=34%) are to LSD1 gene expressions
The phenomenon that combination inhibiting rate 48%, this 2 1+1 ＜, embodies pennogenin -3-O- α-L-Rha (1 → 2) [α-in the composition
L-Rha (1 → 4)] there are the effects for significantly cooperate with inhibition LSD1 gene expressions in-β-D-Glc and other 4 kinds of ingredients.
Description of the drawings
Fig. 1 is the influence of paris polyphylla drug and composition to the expression of HeLa cell p62 genes；
Fig. 2 is the influence of paris polyphylla drug and composition to the expression of HO-8910 Proliferation of Human Ovarian Cell LSD1 genes.
Specific implementation mode
It is specific with reference to the accompanying drawings and examples to introduce essentiality content of the present invention, but protection of the present invention is not limited with this
Range.
One, experiment material
Paris polyphylla medicinal material is purchased from Bozhou medicinal material market, and the place of production is Lijiang, yunnan, is dried overnight for 55 DEG C after crushing, kept dry
It is spare.
1100 liquid chromatographs of Agilent；Sartorius BS210S type electronic balances, Beijing Sai Duolisi instruments system
Unite Co., Ltd；Sartorius CP225D type electronic balances, Beijing Sai Duolisi instrument systems Co., Ltd；Acetonitrile (chromatography
It is pure), methanol (chromatographically pure) be purchased from the U.S. world (TEDIA)；Water is Wahaha Pure Water.
RNAiso plus reagents, SYBRGreen PCR Master Mix and PrimeScript R kits are purchased from
TaKaRa。
Two, experimental method
1, chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc
(PGRR), the assay of chonglou saponin H, chonglou saponin II, Gracillin, chonglou saponin I in paris polyphylla
HPLC methods include following chromatographic parameter：
Chromatograph：1100 liquid chromatographs of Agilent
Chromatographic column：Agilent ZORBAX Extend-C18 liquid-phase chromatographic columns (250mm × 4.6mm, 5 μm)；
Mobile phase：Acetonitrile (A)-water (B)；
Elution program：0~10min, 20%~30%A；10~20min, 30%~40%A；20~35min, 40%~
50%A；35~45min, 50%~60%A；45~55min, 60%~80%A；55~60min, 80%~100%A；
Column temperature：30℃.
Detection wavelength：210nm.
Flow rate of mobile phase：1.0mL/min.
Sample size：20μL.
The preparation of test solution：By paris polyphylla pulverizing medicinal materials, 40 mesh sieve is crossed, precision weighs 10g, sets in round-bottomed flask,
70% ethyl alcohol 40mL, water-bath reflux 2h is added, filtration takes filtrate, is repeated 3 times.Merging filtrate boils off drying after ethyl alcohol, obtains powder
End.Powder is dissolved in 250mL methanol, cross miillpore filter to get.
Precision measures 20 μ L of test solution and injects liquid chromatograph, with standard items external standard method chonglou saponin VII, partially
Promise saponin(e -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc (PGRR), chonglou saponin H, chonglou saponin II, fibre
The thin content of Dioscin, chonglou saponin I in paris polyphylla.
2, cell culture
Adenocarcinoma of the uterine cervix HeLa cells, HO-8910 Proliferation of Human Ovarian Cell are respectively in the DMEM in high glucose training containing 10% fetal calf serum
It supports in base, 37 DEG C, 5%CO2Under the conditions of secondary culture.Logarithmic growth phase cell is for testing.
3, medicine preparation
Paris polyphylla drug：By paris polyphylla pulverizing medicinal materials, 40 mesh sieve is crossed, precision weighs 10g, sets in round-bottomed flask, is added
70% ethyl alcohol 40mL, water-bath reflux 2h, filtration take filtrate, are repeated 3 times.Merging filtrate boils off drying after ethyl alcohol, obtains powder.
Composition medicine ingredient type such as following table, each ingredient are blent according to the content ratio in paris polyphylla with standard items
It is made.
| Serial number | Quantity | Ingredient type |
| Composition medicine 1 | 5 | Chonglou saponin VII, PGRR, chonglou saponin H, chonglou saponin II, Gracillin |
| Composition medicine 2 | 5 | Chonglou saponin VII, PGRR, chonglou saponin II, Gracillin, chonglou saponin I |
| Composition medicine 3 | 4 | Chonglou saponin VII, chonglou saponin H, chonglou saponin II, Gracillin |
| Composition medicine 4 | 4 | Chonglou saponin VII, chonglou saponin II, Gracillin, chonglou saponin I |
| Composition medicine 5 | 1 | PGRR |
4, it is grouped and is administered
By a concentration of 5.5 × 104The HeLa cell suspension inoculations of/mL after culture for 24 hours, are separately added into Yunnan in 96 orifice plates
Paris polyphylla drug, composition medicine 1, composition medicine 3, composition medicine 5 make its final concentration be equivalent to 250 μ g/ of paris polyphylla medicinal material
ML, while negative control group is set, every group of 6 parallel holes, 37 DEG C, 5%CO2After cultivating 48h in cell incubator, supernatant is abandoned in centrifugation
Cell is collected in liquid, PBS washings, spare.
By a concentration of 5.5 × 104The HO-8910 Proliferation of Human Ovarian Cell suspensions of/mL are inoculated in 96 orifice plates, after culture for 24 hours,
Being separately added into paris polyphylla drug, composition medicine 2, composition medicine 4, composition medicine 5 makes its final concentration be equivalent to paris polyphylla
250 μ g/mL of medicinal material, while negative control group is set, every group of 6 parallel holes, 37 DEG C, 5%CO2After 48h being cultivated in cell incubator,
Supernatant is abandoned in centrifugation, and cell is collected in PBS washings, spare.
5, qRT-PCR measures the expression of HeLa cell p62 genes and HO-8910 Proliferation of Human Ovarian Cell LSD1 genes
Above-mentioned cell is collected, cell is washed 3 times with PBS, it is total according to RNAiso Plus kit operation manuals extraction cell
Ultraviolet spectrophotometry row quantitative analysis is used in combination in RNA.Use PrimeScript RT kits by RNA reverse transcriptions for cDNA, with
CDNA is template, using the further row PCR amplification of SYBR-Green PCR Master Mix kits.
P62 upstream region of gene primer sequences are 5 '-TTTTCACTGTCAATTCACTGCA-3 '；
P62 downstream of gene primer sequences are 5 '-GGAGGCGAGGATGGAGGAA-3 '；
LSD1 upstream region of gene primer sequences are 5 '-CAAGTGTCAATTTGTTCGGG-3 '；
LSD1 downstream of gene primer sequences are 5 '-TTCTTTGGGCTGAGGTACTG-3 '；
Internal reference GAPDH upstream region of gene primer sequences are 5 '-GCAAATTCCATGGCACCGTC-3 '；
Internal reference GAPDH downstream of gene primer sequences are 5 '-TCGCCCCACTTGATTTTGG-3 '.
PCR reaction conditions：90 DEG C of 30s, 1 cycle；95 DEG C of 5s, 60 DEG C of 30s, totally 40 recycle.With 2-ΔΔCtIt is worth (Ct generations
Table cycle threshold) indicate p62mRNA, LSD1mRNA relative expression quantity.Experiment is repeated 3 times.
6, statistical method
The statistics and analysis of data is carried out using 5 softwares of Graph Pad Prism.Measurement data is indicated with x ± s, multigroup
Between compare using one-way analysis of variance, compare examined using Tukey two-by-two.P ＜ 0.05 are that difference is statistically significant.
Three, experimental result
1, chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc
(PGRR), the assay result of chonglou saponin H, chonglou saponin II, Gracillin, chonglou saponin I in paris polyphylla
Chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc (PGRR),
The content of chonglou saponin H, chonglou saponin II, Gracillin, chonglou saponin I in paris polyphylla is as shown in the table.
| Compound name | Content (mg/g) | Compound name | Content (mg/g) |
| Chonglou saponin VII | 26.25 | Chonglou saponin II | 30.46 |
| PGRR | 10.50 | Gracillin | 1.95 |
| Chonglou saponin H | 4.18 | Chonglou saponin I | 96.52 |
2, the influence of paris polyphylla drug and composition to the expression of HeLa cell p62 genes
The expression of paris polyphylla drug, composition medicine 1, composition medicine 3, composition medicine 5 to HeLa cell p62 genes
Horizontal influence is as shown in following table and Fig. 1.
| Group | p62mRNA/GAPDHmRNA | Inhibiting rate |
| Negative control group | 1.00 | / |
| Paris polyphylla drug (is equivalent to 250 μ g/mL of paris polyphylla medicinal material) | 0.45 | 55% |
| Composition medicine 1 (is equivalent to 250 μ g/mL of paris polyphylla medicinal material) | 0.47 | 53% |
| Composition medicine 3 (is equivalent to 250 μ g/mL of paris polyphylla medicinal material) | 0.81 | 19% |
| Composition medicine 5 (is equivalent to 250 μ g/mL of paris polyphylla medicinal material) | 0.89 | 11% |
Above-mentioned experimental result explanation：
(1) by chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, again
The composition of building saponin(e H, chonglou saponin II and Gracillin composition substantially can be with equivalent substitution paris polyphylla to p62 gene tables
The depression effect reached, the two intensity are suitable；The composition can be used for equivalent substitution paris polyphylla and prepare p62 gene expression inhibitions
Agent；One skilled in the art will appreciate that inhibition p62 gene expressions can effectively inhibit proliferation (the RNA AF panels of cervical cancer cell
Influence of the p62 gene expressions to proliferation of cervical cancer HeLa cell, Bengbu Medical College's journal the 1st phase of volume 43 in January, 2018), because
This, the composition can be used for equivalent substitution paris polyphylla and prepare treatment of human cervical cancer drug；
(2) by chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, again
In the composition of building saponin(e H, chonglou saponin II and Gracillin composition, pennogenin -3-O- α-L-Rha (1 → 2) [α -
L-Rha (1 → 4)]-β-D-Glc are 11% to the independent inhibiting rate of p62 gene expressions, other 4 kinds of ingredients are to p62 gene expressions
Combination inhibiting rate be 19%, group of significantly less than the 5 kinds ingredients of sum of the two (11%+19%=30%) to p62 gene expressions
The phenomenon that conjunction inhibiting rate 53%, this 2 1+1 ＜, embodies pennogenin -3-O- α-L-Rha (1 → 2) [α-L- in the composition
Rha (1 → 4)] there are the effects for significantly cooperate with inhibition p62 gene expressions in-β-D-Glc and other 4 kinds of ingredients.
3, the influence of paris polyphylla drug and composition to the expression of HO-8910 Proliferation of Human Ovarian Cell LSD1 genes
Paris polyphylla drug, composition medicine 2, composition medicine 4, composition medicine 5 are to HO-8910 Proliferation of Human Ovarian Cell
The influence of the expression of LSD1 genes is as shown in following table and Fig. 2.
| Group | LSD1mRNA/GAPDH mRNA | Inhibiting rate |
| Negative control group | 1.00 | / |
| Paris polyphylla drug (is equivalent to 250 μ g/mL of paris polyphylla medicinal material) | 0.53 | 47% |
| Composition medicine 2 (is equivalent to 250 μ g/mL of paris polyphylla medicinal material) | 0.52 | 48% |
| Composition medicine 4 (is equivalent to 250 μ g/mL of paris polyphylla medicinal material) | 0.78 | 22% |
| Composition medicine 5 (is equivalent to 250 μ g/mL of paris polyphylla medicinal material) | 0.88 | 12% |
Above-mentioned experimental result explanation：
(1) by chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, again
The composition of building saponin I I, Gracillin and chonglou saponin I compositions substantially can be with equivalent substitution paris polyphyllas to LSD1 genes
The depression effect of expression, the two intensity are suitable；The composition can be used for equivalent substitution paris polyphylla and prepare LSD1 gene expressions suppression
Preparation；One skilled in the art will appreciate that inhibition LSD1 gene expressions can effectively inhibit proliferation (the silence LSD1 of ovarian cancer cell
The expression of gene can inhibit the proliferation of oophoroma HO8910 cells and induce its apoptosis, tumour the 5th phase of volume 36 in May, 2016),
Therefore, the composition can be used for equivalent substitution paris polyphylla and prepare treatment of ovarian cancer drug；
(2) by chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, again
In the composition of building saponin I I, Gracillin and chonglou saponin I compositions, pennogenin -3-O- α-L-Rha (1 → 2) [α -
L-Rha (1 → 4)]-β-D-Glc are 12% to the independent inhibiting rate of LSD1 gene expressions, other 4 kinds of ingredients are to LSD1 gene tables
The combination inhibiting rate reached is 22%, and significantly less than 5 kinds ingredients of sum of the two (12%+22%=34%) are to LSD1 gene expressions
The phenomenon that combination inhibiting rate 48%, this 2 1+1 ＜, embodies pennogenin -3-O- α-L-Rha (1 → 2) [α-in the composition
L-Rha (1 → 4)] there are the effects for significantly cooperate with inhibition LSD1 gene expressions in-β-D-Glc and other 4 kinds of ingredients.
Claims (10)
1. a kind of composition preparing p62 gene expression inhibitors for equivalent substitution paris polyphylla, it is characterised in that：
By chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, chonglou saponin
H, chonglou saponin II and Gracillin composition.
2. application of the composition described in claim 1 in terms of equivalent substitution paris polyphylla prepares p62 gene expression inhibitors.
3. a kind of composition preparing treatment of human cervical cancer drug for equivalent substitution paris polyphylla, it is characterised in that：
By chonglou saponin VII, pennogenin -3-O- α-L-Rha (1 → 2) [α-L-Rha (1 → 4)]-β-D-Glc, chonglou saponin
H, chonglou saponin II and Gracillin composition.
4. application of the composition described in claim 1 in terms of equivalent substitution paris polyphylla prepares treatment of human cervical cancer drug.
5. a kind of HPLC methods measuring each chemical composition content in paris polyphylla in composition described in claim 1, special
Sign is, including following chromatographic parameter：
Chromatographic column：C18 filler chromatographic columns；
Mobile phase：Acetonitrile (A)-water (B)；
Elution program：0~10min, 20%~30%A；10~20min, 30%~40%A；20~35min, 40%~50%
A；35~45min, 50%~60%A；45~55min, 60%~80%A；55~60min, 80%~100%A.
6. HPLC methods according to claim 3, it is characterised in that：Using 1100 liquid chromatographs of Agilent.
7. HPLC methods according to claim 3, it is characterised in that：Using Agilent ZORBAX Extend-C18 liquid
Phase chromatographic column (250mm × 4.6mm, 5 μm).
8. HPLC methods according to claim 3, it is characterised in that：Column temperature is 30 DEG C.
9. HPLC methods according to claim 3, it is characterised in that：Detection wavelength is 210nm.
10. HPLC methods according to claim 3, it is characterised in that：Flow rate of mobile phase is 1.0mL/min.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810456610.0A CN108635363B (en) | 2018-05-14 | 2018-05-14 | A kind of composition and its measuring method preparing treatment of human cervical cancer drug for substituting paris polyphylla |
| PCT/CN2018/103855 WO2019218543A1 (en) | 2018-05-14 | 2018-09-03 | Discovery and pharmaceutical use of equivalent component group of traditional chinese medicine rhizoma paridis yunnanensis, scutellaria indica, fructus xanthii sibirici, or bupleurum bicaule helm |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810456610.0A CN108635363B (en) | 2018-05-14 | 2018-05-14 | A kind of composition and its measuring method preparing treatment of human cervical cancer drug for substituting paris polyphylla |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108635363A true CN108635363A (en) | 2018-10-12 |
| CN108635363B CN108635363B (en) | 2019-06-04 |
Family
ID=63755325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810456610.0A Active CN108635363B (en) | 2018-05-14 | 2018-05-14 | A kind of composition and its measuring method preparing treatment of human cervical cancer drug for substituting paris polyphylla |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108635363B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019218543A1 (en) * | 2018-05-14 | 2019-11-21 | Yang Zhenhui | Discovery and pharmaceutical use of equivalent component group of traditional chinese medicine rhizoma paridis yunnanensis, scutellaria indica, fructus xanthii sibirici, or bupleurum bicaule helm |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693035A (en) * | 2009-10-15 | 2010-04-14 | 天津大学 | Medicinal preparation with inhibiting effect on tumor metastasis |
-
2018
- 2018-05-14 CN CN201810456610.0A patent/CN108635363B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693035A (en) * | 2009-10-15 | 2010-04-14 | 天津大学 | Medicinal preparation with inhibiting effect on tumor metastasis |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019218543A1 (en) * | 2018-05-14 | 2019-11-21 | Yang Zhenhui | Discovery and pharmaceutical use of equivalent component group of traditional chinese medicine rhizoma paridis yunnanensis, scutellaria indica, fructus xanthii sibirici, or bupleurum bicaule helm |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108635363B (en) | 2019-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Simultaneous quantification of six major phenolic acids in the roots of Salvia miltiorrhiza and four related traditional Chinese medicinal preparations by HPLC–DAD method | |
| Wang et al. | Hydrophobic flavonoids from Scutellaria baicalensis induce colorectal cancer cell apoptosis through a mitochondrial-mediated pathway | |
| Xiao et al. | Chemical and genetic assessment of variability in commercial Radix Astragali (Astragalus spp.) by ion trap LC− MS and nuclear ribosomal DNA barcoding sequence analyses | |
| Wen et al. | Chemical characteristics of saponins from Paris fargesii var. brevipetala and cytotoxic activity of its main ingredient, paris saponin H | |
| Zhang et al. | Hierarchical extraction and simultaneous determination of flavones and triterpenes in different parts of Trichosanthes kirilowii Maxim. by ultra-high-performance liquid chromatography coupled with tandem mass spectrometry | |
| CN108003214A (en) | A kind of saponin compound and its methods and applications extracted from the rhizoma bolbostemmae | |
| Chen et al. | Network pharmacology-based strategy for elucidating the molecular basis Forthe pharmacologic effects of Licorice (Glycyrrhiza spp.) | |
| Ji et al. | Integrated phytochemical analysis based on UPLC–MS/MS and network pharmacology approaches to explore the effect of Odontites vulgaris Moench on rheumatoid arthritis | |
| Wu et al. | Study on the substance basis of the efficacy of eucommiae cortex before and after salt processing for the treatment of kidney-yang deficiency syndrome based on the spectrum-effect relationship | |
| CN103099832B (en) | Method for biotransformation of pseudo-ginseng by using Candida | |
| Hu et al. | Chemical constituents from Physalis Calyx seu Fructus and their inhibitory effects against oxidative stress and inflammatory response | |
| CN108635363B (en) | A kind of composition and its measuring method preparing treatment of human cervical cancer drug for substituting paris polyphylla | |
| Yang et al. | Gancao Xiexin Decoction inhibits gastric carcinoma proliferation and migration by regulating the JAK2/STAT3 signalling pathway | |
| Liu et al. | 5-Desmethylsinensetin isolated from Artemisia princeps suppresses the stemness of breast cancer cells via Stat3/IL-6 and Stat3/YAP1 signaling | |
| Ding et al. | Exploring the anti-inflammatory effect of Fructus Gleditsia sinensis Lam., Fructus Gleditsiae abnormalis, and Gymnocladus chinensis Baill. using SPME-GC-MS, network pharmacology, and molecular docking | |
| Wang et al. | Antitumor evaluation and multiple analysis on different extracted fractions of the root of Cynanchum auriculatum Royle ex Wight | |
| Lin et al. | Simultaneous determination of furostanol, pennogenyl, and diosgenyl glycosides in Taiwanese Rhizoma Paridis (Paris formosana Hayata) by high-performance liquid chromatography with evaporative light scattering detection | |
| CN108451966A (en) | It is a kind of to be used to substitute composition and its assay method that paris polyphylla prepares treatment of ovarian cancer drug | |
| CN108721312A (en) | A kind of composition and its assay method preparing glioma treatment drug for substituting Radix Bupleuri bicaulis | |
| CN108434168A (en) | It is a kind of to be used to substitute composition and its assay method that Radix Bupleuri bicaulis prepares drugs for prostate cancer | |
| Qiu et al. | Protective effect of total glycosides from lily on H2O2-induced H9C2 cells mitochondrial damage and characterization of the chemical profiles by UHPLC-LTQ-Orbitrap-MSn | |
| CN108714147A (en) | A kind of composition and its assay method preparing glioma treatment drug for substituting the achene of Siberian cocklebur | |
| CN102908410A (en) | Chinese rhubarb extract for treating osteoporosis and climacteric syndrome | |
| Vallinayagam et al. | Pro-apoptotic property of phytocompounds from Naringi crenulata in HER2+ breast cancer cells in vitro | |
| CN101926921A (en) | Liriope muscari total saponin and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190422 Address after: 518114 Room 301, Xia Li Lang Village Committee Office Building, No. 1 Xia Li Bei Road, Nanwan Street, Longgang District, Shenzhen City, Guangdong Province Applicant after: Shenzhen Shenchuang Biotechnology Co., Ltd. Address before: 210009 Tongjiaxiang No. 24, Gulou District, Nanjing City, Jiangsu Province, China Pharmaceutical University Applicant before: Yang Zhenhui |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |